Flinton Capital Management LLC Has $293,000 Stake in Astrazeneca PLC (AZN)

Flinton Capital Management LLC held its stake in shares of Astrazeneca PLC (NYSE:AZN) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,592 shares of the company’s stock at the close of the 2nd quarter. Flinton Capital Management LLC’s holdings in Astrazeneca PLC were worth $293,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. Garrison Financial Corp increased its stake in Astrazeneca PLC by 0.5% in the 2nd quarter. Garrison Financial Corp now owns 18,058 shares of the company’s stock valued at $616,000 after buying an additional 86 shares during the last quarter. Dorsey & Whitney Trust CO LLC increased its stake in Astrazeneca PLC by 0.7% in the 2nd quarter. Dorsey & Whitney Trust CO LLC now owns 13,315 shares of the company’s stock valued at $454,000 after buying an additional 94 shares during the last quarter. NEXT Financial Group Inc increased its stake in Astrazeneca PLC by 1.8% in the 2nd quarter. NEXT Financial Group Inc now owns 6,463 shares of the company’s stock valued at $220,000 after buying an additional 115 shares during the last quarter. Atria Investments LLC increased its stake in Astrazeneca PLC by 0.5% in the 2nd quarter. Atria Investments LLC now owns 24,695 shares of the company’s stock valued at $842,000 after buying an additional 129 shares during the last quarter. Finally, Financial Counselors Inc. increased its stake in Astrazeneca PLC by 2.7% in the 2nd quarter. Financial Counselors Inc. now owns 6,871 shares of the company’s stock valued at $234,000 after buying an additional 182 shares during the last quarter. Hedge funds and other institutional investors own 14.17% of the company’s stock.

Several brokerages have issued reports on AZN. BNP Paribas upgraded shares of Astrazeneca PLC from a “neutral” rating to an “outperform” rating in a research note on Monday, September 25th. Sanford C. Bernstein reiterated a “buy” rating on shares of Astrazeneca PLC in a research note on Friday, September 22nd. Liberum Capital lowered shares of Astrazeneca PLC from a “buy” rating to a “hold” rating in a research note on Thursday, September 14th. BMO Capital Markets began coverage on shares of Astrazeneca PLC in a research note on Wednesday, September 6th. They issued an “outperform” rating and a $38.00 price target on the stock. Finally, Natixis upgraded shares of Astrazeneca PLC from a “neutral” rating to a “buy” rating in a research note on Wednesday, September 6th. Four analysts have rated the stock with a sell rating, eleven have assigned a hold rating and fourteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $34.35.

Shares of Astrazeneca PLC (AZN) opened at 34.53 on Friday. The company has a market cap of $87.43 billion, a P/E ratio of 22.65 and a beta of 0.76. The company’s 50 day moving average is $32.51 and its 200 day moving average is $32.24. Astrazeneca PLC has a one year low of $25.55 and a one year high of $35.60.

Astrazeneca PLC (NYSE:AZN) last posted its quarterly earnings data on Thursday, July 27th. The company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.46. Astrazeneca PLC had a net margin of 17.80% and a return on equity of 35.90%. The business had revenue of $5.05 billion during the quarter, compared to the consensus estimate of $5.04 billion. During the same quarter last year, the company posted $0.83 earnings per share. The firm’s quarterly revenue was down 9.9% compared to the same quarter last year. On average, equities analysts predict that Astrazeneca PLC will post $1.91 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Flinton Capital Management LLC Has $293,000 Stake in Astrazeneca PLC (AZN)” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://sportsperspectives.com/2017/10/13/flinton-capital-management-llc-has-293000-stake-in-astrazeneca-plc-azn.html.

Astrazeneca PLC Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca PLC (NYSE:AZN).

Institutional Ownership by Quarter for Astrazeneca PLC (NYSE:AZN)

Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply